NCT03756818: TAK-659 and Paclitaxel in Treating Patients With Advanced Solid Tumors

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: KRAS
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Tyrosine-Kinase Inhibitor, Chemotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients must have KRAS+ tumor(s) to be eligible; Patients must have received a prior therapy with a taxane
Exclusions: Patients with active brain metastases or leptomeningeal metastases

Comments are closed.

Up ↑